| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $96,933 | 3 | 14 |
Sells | $85,389 | 18 | 86 |
| Cowan Chad | Chief Scientific Officer | 1 | $49,252 | 1 | $2,736 | $46,516 |
| Pfeiffenberger Brent | President and CEO | 2 | $47,681 | 1 | $14,735 | $32,946 |
| Carr Douglas | SVP Finance & Operations | 0 | $0 | 10 | $27,949 | $-27,949 |
| Russotti Gregory | See Remarks | 0 | $0 | 7 | $40,140 | $-40,140 |
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several …
Over the last 12 months, insiders at Century Therapeutics, Inc. have bought $96,933 and sold $85,389 worth of Century Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Century Therapeutics, Inc. have bought $52,295 and sold $1.65M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cowan Chad (Chief Scientific Officer) — $49,252. Pfeiffenberger Brent (President and CEO) — $47,681.
The last purchase of 58,060 shares for transaction amount of $49,252 was made by Cowan Chad (Chief Scientific Officer) on 2025‑12‑22.
| 2026-09-14 | Sale | Russotti Gregory | See Remarks | 2,587 0.0012% | $1.93 | $4,993 | -24.50% | |
| 2026-09-14 | Sale | Carr Douglas | SVP Finance & Operations | 1,658 0.0008% | $1.93 | $3,200 | -24.50% | |
| 2026-09-08 | Sale | Russotti Gregory | See Remarks | 534 0.0003% | $2.05 | $1,095 | -24.88% | |
| 2026-09-08 | Sale | Carr Douglas | SVP Finance & Operations | 254 0.0001% | $2.05 | $521 | -24.88% | |
| 2026-08-03 | Sale | Carr Douglas | SVP Finance & Operations | 275 0.0003% | $1.98 | $544 | -6.06% | |
| 2026-06-12 | Sale | Russotti Gregory | See Remarks | 2,584 0.003% | $2.23 | $5,767 | -10.67% | |
| 2026-06-12 | Sale | Carr Douglas | SVP Finance & Operations | 1,654 0.0019% | $2.23 | $3,692 | -10.67% | |
| 2026-06-08 | Sale | Russotti Gregory | See Remarks | 524 0.0006% | $2.11 | $1,106 | -4.72% | |
| 2026-06-08 | Sale | Carr Douglas | SVP Finance & Operations | 249 0.0003% | $2.11 | $526 | -4.72% | |
| 2026-05-04 | Sale | Carr Douglas | SVP Finance & Operations | 264 0.0003% | $2.34 | $618 | -8.73% | |
| 2026-03-12 | Sale | Russotti Gregory | See Remarks | 10,076 0.0118% | $2.55 | $25,684 | -13.20% | |
| 2026-03-12 | Sale | Carr Douglas | SVP Finance & Operations | 7,043 0.0082% | $2.55 | $17,953 | -13.20% | |
| 2026-03-09 | Sale | Russotti Gregory | See Remarks | 479 0.0005% | $2.54 | $1,215 | -26.19% | |
| 2026-02-03 | Sale | Carr Douglas | SVP Finance & Operations | 323 0.0004% | $1.82 | $589 | +16.85% | |
| 2025-12-22 | Cowan Chad | Chief Scientific Officer | 58,060 0.0666% | $0.85 | $49,252 | +147.99% | ||
| 2025-12-12 | Pfeiffenberger Brent | President and CEO | 52,000 0.0629% | $0.58 | $30,352 | +280.13% | ||
| 2025-12-08 | Sale | Carr Douglas | SVP Finance & Operations | 257 0.0003% | $0.53 | $137 | +270.18% | |
| 2025-12-08 | Sale | Russotti Gregory | See Remarks | 526 0.0006% | $0.53 | $280 | +270.18% | |
| 2025-11-20 | Sale | Cowan Chad | Chief Scientific Officer | 5,462 0.0065% | $0.50 | $2,736 | +325.92% | |
| 2025-11-19 | Pfeiffenberger Brent | President and CEO | 35,000 0.0387% | $0.50 | $17,329 | +304.33% |
| Pfeiffenberger Brent | President and CEO | 3322990 1.8351% | $5.05M | 2 | 6 | |
| Cowan Chad | Chief Scientific Officer | 1045087 0.5772% | $1.59M | 1 | 1 | |
| BAYER AKTIENGESELLSCHAFT | 10 percent owner | 12675838 7.0003% | $19.27M | 1 | 0 | <0.0001% |
| Casdin Eli | director | 3206380 1.7707% | $4.87M | 1 | 0 | <0.0001% |
| Versant Venture Capital VI, L.P. | 10 percent owner | 714095 0.3944% | $1.09M | 1 | 0 | <0.0001% |
| Quimi Daphne | director | 5000 0.0028% | $7,600.00 | 1 | 0 | <0.0001% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$2,516,932 | 19 | -15.78% | $252.7M |
| Increased Positions | 17 | +21.25% | 12M | +59.9% |
| Decreased Positions | 32 | -40% | 7M | -33.16% |
| New Positions | 8 | New | 9M | New |
| Sold Out Positions | 16 | Sold Out | 5M | Sold Out |
| Total Postitions | 65 | -18.75% | 26M | +26.74% |
| Bain Capital Life Sciences Investors, Llc | $3,521.00 | 4.07% | 3.54M | -2M | -34.6% | 2025-09-30 |
| Renaissance Technologies Llc | $2,574.00 | 2.97% | 2.59M | +564,400 | +27.91% | 2025-09-30 |
| Vanguard Group Inc | $2,093.00 | 2.42% | 2.1M | -6,213 | -0.29% | 2025-09-30 |
| Dafna Capital Management Llc | $1,696.00 | 1.96% | 1.7M | 0 | 0% | 2025-09-30 |
| Casdin Capital, Llc | $1,222.00 | 1.41% | 1.23M | 0 | 0% | 2025-09-30 |
| Syncona Portfolio Ltd | $1,207.00 | 1.39% | 1.21M | 0 | 0% | 2025-09-30 |
| Two Sigma Investments, Lp | $907.00 | 1.05% | 911,446 | +338,902 | +59.19% | 2025-09-30 |
| Tang Capital Management Llc | $896.00 | 1.03% | 900,000 | 0 | 0% | 2025-09-30 |
| Two Sigma Advisers, Lp | $853.00 | 0.99% | 857,600 | +490,500 | +133.62% | 2025-09-30 |
| Millennium Management Llc | $740.00 | 0.86% | 743,781 | -68,432 | -8.43% | 2025-09-30 |